GlassScriptPhysician profile
Samuel Guba
NPI 1326669409
$4,619.54
in general payments reported to CMS, 2019-2025
13 companies · $2,171 in 2025
The $2,171 reported for 2025 was more than what 83% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,305 · 2023: $1,126 · 2024: $17.12 · 2025: $2,171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $2,254 · Travel and Lodging: $540 · Food and Beverage: $520.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $2,254.19 |
| Travel and Lodging | $539.86 |
| Food and Beverage | $520.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,539.86 | 2022-2025 | Davinci Xi |
| Medical Device Business Services, INC. | $305.00 | 2022 | |
| Stryker Corporation | $254.19 | 2025 | |
| Davol INC. | $159.02 | 2025 | Phasix Mesh |
| Acera Surgical, INC. | $138.86 | 2025 | Restrata Wound Matrix |
| Medtronic, INC. | $91.71 | 2023 | Signia |
| Takeda Pharmaceuticals U.S.A., INC. | $38.80 | 2025 | Gattex |
| Heron Therapeutics, INC. | $21.27 | 2023 | Zynrelef |
| Hologic Sales and Service, LLC | $17.12 | 2024 | Coolseal Generator |
| Novo Nordisk INC | $14.83 | 2025 | Wegovy |
| Vertex Pharmaceuticals Incorporated | $13.99 | 2025 | |
| Boston Scientific Corporation | $13.39 | 2023 | Agile Esophageal |
| Kerecis Limited | $11.50 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Guba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.